ArticleESMO gastrointestinal oncology2026

Exploratory analysis of HER2-positive/CLDN18.2-positive metastatic gastric and gastroesophageal junction cancer toward future therapeutic development.

D Okemoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.